HUP0204156A2 - Humán interleukin-1 béta elleni rekombináns antitestek - Google Patents

Humán interleukin-1 béta elleni rekombináns antitestek

Info

Publication number
HUP0204156A2
HUP0204156A2 HU0204156A HUP0204156A HUP0204156A2 HU P0204156 A2 HUP0204156 A2 HU P0204156A2 HU 0204156 A HU0204156 A HU 0204156A HU P0204156 A HUP0204156 A HU P0204156A HU P0204156 A2 HUP0204156 A2 HU P0204156A2
Authority
HU
Hungary
Prior art keywords
beta
human
recombinant antibodies
human interleukin
antibodies
Prior art date
Application number
HU0204156A
Other languages
English (en)
Inventor
Hermann Gram
Franco E. Padova
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0204156(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP0204156A2 publication Critical patent/HUP0204156A2/hu
Publication of HUP0204156A3 publication Critical patent/HUP0204156A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

A találmány IL-1b-t kötő molekulákra, különösen humán IL-1b elleniantitestekre, előnyösen egy humán IL-1b elleni humán antitestrevonatkozik, melyben a nehéz és könnyű lánc CDR-jei meghatározottaminosavszekvenciával rendelkeznek. A találmány tárgyát képezi továbbáezeknek az antitesteknek az előállítása és alkalmazása IL-l-mediáltbetegségek vagy rendellenességek kezelésében, mint pl.oszteoartritisz, oszteoporózis vagy egyéb gyulladásos artritiszek. Ó
HU0204156A 2000-01-21 2001-01-19 Recombinant antibodies to human interleukin-1 beta HUP0204156A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0001448.0A GB0001448D0 (en) 2000-01-21 2000-01-21 Organic compounds
PCT/EP2001/000591 WO2001053353A2 (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interkleukin-1 beta

Publications (2)

Publication Number Publication Date
HUP0204156A2 true HUP0204156A2 (hu) 2003-03-28
HUP0204156A3 HUP0204156A3 (en) 2005-09-28

Family

ID=9884137

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204156A HUP0204156A3 (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interleukin-1 beta

Country Status (33)

Country Link
US (4) US20030124617A1 (hu)
EP (1) EP1248804B2 (hu)
JP (2) JP3978338B2 (hu)
KR (1) KR100697126B1 (hu)
CN (1) CN1395581B (hu)
AR (1) AR027253A1 (hu)
AT (1) ATE346868T1 (hu)
AU (1) AU772949B2 (hu)
BR (1) BR0107661A (hu)
CA (1) CA2396212C (hu)
CO (1) CO5261584A1 (hu)
CY (1) CY1107989T1 (hu)
CZ (1) CZ302738B6 (hu)
DE (1) DE60124863T3 (hu)
DK (1) DK1248804T4 (hu)
ES (1) ES2274865T5 (hu)
GB (1) GB0001448D0 (hu)
HK (1) HK1050013A1 (hu)
HU (1) HUP0204156A3 (hu)
IL (2) IL150551A0 (hu)
MX (1) MXPA02007091A (hu)
MY (1) MY155269A (hu)
NO (1) NO329816B1 (hu)
NZ (1) NZ519936A (hu)
PE (1) PE20011219A1 (hu)
PL (1) PL207642B1 (hu)
PT (1) PT1248804E (hu)
RU (1) RU2264413C2 (hu)
SI (1) SI1248804T2 (hu)
SK (1) SK288054B6 (hu)
TR (1) TR200201780T2 (hu)
WO (1) WO2001053353A2 (hu)
ZA (1) ZA200205659B (hu)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
EP1297142B1 (en) 2000-06-29 2009-01-14 Abbott Laboratories Dual specificity antibodies and methods of making and using
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
KR20040077889A (ko) * 2002-01-28 2004-09-07 메다렉스, 인코포레이티드 전립선 특이적 막 항원 (ｐｓｍａ)에 대한 인간모노클로날 항체
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
EP2280286A1 (en) * 2003-09-15 2011-02-02 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate systemic lupus erythematosus
DK2270045T3 (en) 2004-02-06 2015-04-07 Univ Massachusetts ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINES AND APPLICATIONS THEREOF
EP1851245B1 (en) * 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
PE20061324A1 (es) * 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
MX2007016032A (es) 2005-06-21 2008-03-10 Xoma Technology Ltd Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
ES2944067T3 (es) * 2005-10-26 2023-06-19 Novartis Ag Uso de anticuerpos anti il-1beta
EA035459B1 (ru) * 2005-12-29 2020-06-19 Сентокор, Инк. Антитело против il-23p19
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
KR20110079922A (ko) * 2006-04-14 2011-07-11 노파르티스 아게 안과 장애 치료를 위한 ｉｌ－1 항체의 용도
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
RU2554747C9 (ru) 2006-12-20 2015-10-20 Ксома (Сша) Ллс Способы лечения il-1бета-зависимых заболеваний
US8324350B2 (en) * 2006-12-29 2012-12-04 Abbott Laboratories Dual-specific IL-1α/IL-1β antibodies
WO2008106131A2 (en) 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
CA3213888A1 (en) * 2007-05-29 2008-12-04 Novartis Ag New indications for anti-il-i-beta therapy
CA2710252C (en) * 2007-12-20 2017-03-28 Xoma Technology Ltd. Methods for the treatment of gout
ES2398693T3 (es) * 2008-06-06 2013-03-21 Xoma Technology Ltd. Métodos para el tratamiento de la artritis reumatoide
US8377429B2 (en) 2008-09-05 2013-02-19 Xoma Technology Ltd. Methods for improvement of beta cell function with anti-IL-1β antibodies or fragments thereof
KR102071834B1 (ko) 2009-10-26 2020-01-30 에프. 호프만-라 로슈 아게 글리코실화된 면역글로불린의 제조 방법
BR112012028557A2 (pt) * 2010-05-07 2019-09-24 Xoma Technology Ltd. uso de um anticorpo anti-il-1b ou de fragmentos de ligação do mesmo.
DE102010033565B4 (de) * 2010-07-27 2012-06-21 Tetec Tissue Engineering Technologies Ag Marker zur Bestimmung von Chondrozyten
NZ606824A (en) 2010-08-02 2015-05-29 Regeneron Pharma Mice that make binding proteins comprising vl domains
CN103328511B (zh) * 2010-09-10 2016-01-20 埃派斯进有限公司 抗-IL-1β抗体及其使用方法
PL2578688T5 (pl) 2011-02-25 2023-05-29 Regeneron Pharmaceuticals, Inc. Myszy adam6
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
DE102011083595A1 (de) 2011-09-28 2013-03-28 Bayer Pharma AG Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
EP3050900A1 (en) 2011-12-19 2016-08-03 Xoma (Us) Llc Methods for treating acne
CA2859408C (en) 2011-12-20 2020-06-16 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
SG10201708562VA (en) 2012-02-13 2017-12-28 Agency Science Tech & Res IL-1β Neutralizing Human Monoclonal Antibodies
KR102436654B1 (ko) 2012-06-12 2022-08-26 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
AU2015231025A1 (en) 2014-03-21 2016-09-15 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
KR102601491B1 (ko) 2014-03-21 2023-11-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
AU2019383017A1 (en) 2018-11-20 2021-06-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772685A (en) 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
FR2640146B1 (fr) * 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3714683B2 (ja) * 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
US5429614A (en) 1993-06-30 1995-07-04 Baxter International Inc. Drug delivery system
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
DE60124863T3 (de) 2010-05-20
CN1395581A (zh) 2003-02-05
GB0001448D0 (en) 2000-03-08
HK1050013A1 (zh) 2003-06-06
PL356297A1 (en) 2004-06-28
CZ20022531A3 (cs) 2002-10-16
HUP0204156A3 (en) 2005-09-28
IL150551A0 (en) 2003-02-12
SK10352002A3 (sk) 2003-03-04
CZ302738B6 (cs) 2011-10-12
DE60124863D1 (de) 2007-01-11
WO2001053353A2 (en) 2001-07-26
PL207642B1 (pl) 2011-01-31
AR027253A1 (es) 2003-03-19
JP3978338B2 (ja) 2007-09-19
ES2274865T5 (es) 2010-04-19
EP1248804A2 (en) 2002-10-16
ES2274865T3 (es) 2007-06-01
CN1395581B (zh) 2010-10-13
MY155269A (en) 2015-09-30
DK1248804T3 (da) 2007-02-26
PT1248804E (pt) 2007-02-28
EP1248804B1 (en) 2006-11-29
SK288054B6 (sk) 2013-03-01
NZ519936A (en) 2004-02-27
JP2007097598A (ja) 2007-04-19
US20110182894A1 (en) 2011-07-28
CA2396212C (en) 2013-04-02
US7491392B2 (en) 2009-02-17
ATE346868T1 (de) 2006-12-15
ZA200205659B (en) 2003-12-31
KR100697126B1 (ko) 2007-03-20
DE60124863T2 (de) 2007-04-26
CY1107989T1 (el) 2013-09-04
US20090232803A1 (en) 2009-09-17
AU3369701A (en) 2001-07-31
NO20023266L (no) 2002-08-28
RU2002121649A (ru) 2004-03-10
BR0107661A (pt) 2002-11-19
JP2003520595A (ja) 2003-07-08
NO329816B1 (no) 2010-12-27
CA2396212A1 (en) 2001-07-26
US20060251660A1 (en) 2006-11-09
CO5261584A1 (es) 2003-03-31
NO20023266D0 (no) 2002-07-05
KR20020073178A (ko) 2002-09-19
PE20011219A1 (es) 2001-12-17
SI1248804T2 (sl) 2010-04-30
TR200201780T2 (tr) 2003-01-21
US20030124617A1 (en) 2003-07-03
EP1248804B2 (en) 2009-12-02
IL150551A (en) 2010-11-30
RU2264413C2 (ru) 2005-11-20
WO2001053353A3 (en) 2002-04-04
DK1248804T4 (da) 2010-04-06
SI1248804T1 (sl) 2007-06-30
AU772949B2 (en) 2004-05-13
MXPA02007091A (es) 2002-12-13

Similar Documents

Publication Publication Date Title
HUP0204156A2 (hu) Humán interleukin-1 béta elleni rekombináns antitestek
BR0113420A (pt) Anticorpos para il-1beta humano
HUP0301789A2 (hu) Rekombináns anti CD40 ellenanyagok és használatuk
HUP0402162A2 (hu) A humán angiopoietin-2 specifikus kötőanyagai
RS51829B (sr) Ljudska antitela specifična za interleukin 15 (il-15)
HK1140781A1 (en) Il-1beta binding antibodies and fragments thereof il-1
MX2010003574A (es) Anticuerpos il-23.
SG155186A1 (en) Il-17 antagonistic antibodies
WO2004067568A3 (en) Human il-1 beta antagonists
IL195085A0 (en) Antibody molecules having specifity for human tnf ?? compounds and composition comprising them, dna sequence encoding heavy and light chain of said antibody and process for the production of said antibody
EA200700136A1 (ru) Анти-cd154-антитела
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
WO2003073982A3 (en) Anti-interleukin-1 beta analogs
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
DK1412503T3 (da) Et fusionsprotein
MX2021014885A (es) Composiciones de anticuerpos anti-tnf, y métodos para el tratamiento de la artritis psoriásica.
CA2428319A1 (en) Compositions and methods for diagnosing or treating psoriasis
DE60209797D1 (de) Antikörper zur stimulierung der produktion von il-1ra
TH114402B (th) แอนติบอดีของ il-17 แอนติโกนิสติก
MX2021008871A (es) Composiciones de anticuerpos anti-tnf para usarse en metodos para el tratamiento de la artritis psoriasica.
TH114402A (th) แอนติบอดีของ il-17 แอนติโกนิสติก
TH55112B (th) แอนติบอดีของ il-17 แอนติโกนิสติก
HUP0400839A2 (en) Immunological binding molecules inhibiting the syncytial fusion of trophoblast cells
TH53886A (th) แอนติบอดี้ต่อ il-1b ในมนุษย์
CY1106552T1 (el) Ενωσεις ισοχρωμανιου για την θεραπεια ανωμαλιων του κνς

Legal Events

Date Code Title Description
FC4A Lapse of provisional application due to refusal